top of page

A Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

We worked with Axial and three other sites to assess the safety, tolerability and efficacy of a pharmaceutical therapy called AB-2004.

Phase 1b/2a of the study explored whether AB-2004’s ability to reduce the availability of certain gut bacteria, such as p-cresol, can improve gastrointestinal symptoms and some related behavioural challenges in autistic individuals.

Phase 2b of the study investigated whether treatment with AB-2004 can improve irritability in autistic children. Eligible participants were randomly assigned to receive AB-2004 or a placebo.

You can read more on the study's website

Initial findings are promising and can be read about here.

 

Initial findings are promising and can be read about here.

Results

bottom of page